Here we appear to have a
fortunately rare mutation that results in Parkinson’s. It will add to our knowledge and hopefully a
protocol that eliminates the disease.
Having lost close friends to this
horror, its commonality is typically underestimated. The decline from simple recognition varies substantially.
There appears to be a significant
difference varying with the degree of educational attainment. A certain chess master collapsed over two
years and it was determined that he had late stage disease. Yet he held it off to the very last. Others
slide very quickly and are gone.
This is one disease we really
need a cure for. Bear in mind that is
consider Cancer as cured using nanogold protocol and that circulatory disease
responds well to Vitamin C therapy. It
they are not cured, we are simply not using what we have.
The two nasty brain diseases are
the ones in need.
Genetic Mutation Linked to Parkinson’s Disease
Released: 7/15/2011 12:30 PM EDT
Researchers say mutated gene may play a role in the buildup of proteins
in the brain
Newswise — JACKSONVILLE ,
Fla. — Researchers have
discovered a new gene mutation they say causes Parkinson’s disease.
The mutation was identified in a large Swiss family with Parkinson’s disease,
using advanced DNA sequencing technology.
The study, published today in the American Journal of Human Genetics,
was led by neuroscientists at the Mayo Clinic campus in Florida
and included collaborators from the U.S. ,
Canada , Europe, United Kingdom , Asia and the Middle
East .
“This finding provides an exciting new direction for Parkinson’s
disease research,” says co-author Zbigniew Wszolek, M.D.,
a Mayo Clinic neuroscientist. “Every new gene we discover for Parkinson’s
disease opens up new ways to understand this complex disease, as well as
potential ways of clinically managing it.”
The team found that mutations in VPS35, a protein responsible for
recycling other proteins within cells, caused Parkinson’s disease in the Swiss
family. Mutated VPS35 may impair the ability of a cell to recycle proteins
as needed, which could lead to the kind of errant buildup of protein seen in
some Parkinson’s disease brains and in other diseases like Alzheimer’s
disease says co-author Owen Ross,
Ph.D., a neuroscientist at Mayo Clinic in Florida. “In
fact, expression of this gene has been shown to be reduced in Alzheimer’s disease,
and faulty recycling of proteins within cells has been linked to other
neurodegenerative diseases,” he says.
So far, mutations in six genes have been linked to familial forms of
Parkinson’s disease, with many mutations identified as a direct result of Mayo
Clinic’s collaborative research efforts. Dr. Wszolek has built a worldwide
network of Parkinson’s disease investigators, many of whom have conducted
research at Mayo Clinic. The study’s first author, Carles Vilariño-Güell, Ph.D.,
and the senior investigator, Matthew Farrer, Ph.D., worked on this study while
at Mayo Clinic in 2010; they have since moved to the University
of British Columbia in Vancouver . The joint
first author, neurologist Christian Wilder, M.D., first identified the Swiss
Parkinson’s disease family and continued to study them while he was a research
fellow at Mayo Clinic; he has now returned to Centre Hospitalier Universitaire
Vaudois in Lausanne, Switzerland.
Investigators used a new genetic sequencing technique to find the VPS35
mutation, according to Dr. Ross. They used ‘exome’ sequencing to look for
shared variations in a pair of first cousins within a large Swiss family
affected by Parkinson’s disease. Collectively, exons, which provide the genetic
blueprint used in the production of proteins, make up only 1 percent of the
entire genome and so it is much easier to look for novel variations, causing
changes in the protein sequence, that would represent possible disease-causing
mutations, he says. “Cousins only share about 10 percent of their genome,
whereas parents and children or siblings share much more. This narrowed the
field of novel variations for us,” says Dr. Wszolek, with VPS35 emerging as the
latest Parkinson’s disease gene.
“There is much more we need to know about this gene,” Dr. Ross says.
“Although it appears to be a rare cause of Parkinson’s disease, it seems to be
very important from a mechanistic viewpoint for this disease and possibly other
neurodegenerative disorders.”
The study was funded by grants from the National Institutes of Health,
the Swiss Parkinson’s Disease Foundation, the Michael J. Fox Foundation, a gift
from Carl Edward Bolch, Jr., and Susan Bass Bolch. The sequencing work was
financed by the Parkinson’s Disease Foundation. This work and Dr.
Vilariño-Güell received the AD/Parkinson’s Disease Conference Award donated by
Ms. Evelyn Greenberg in memory of Prof. Moshe Greenberg.
No comments:
Post a Comment